Cara Financial Statements From 2010 to 2025
| 69C Stock | EUR 4.84 0.00 0.00% |
Check Cara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cara Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Cara financial statements analysis is a perfect complement when working with Cara Therapeutics Valuation or Volatility modules.
Cara |
Cara Therapeutics Company Current Valuation Analysis
Cara Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cara Therapeutics Current Valuation | 450.58 M |
Most of Cara Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cara Therapeutics has a Current Valuation of 450.58 M. This is 96.86% lower than that of the Healthcare sector and 90.3% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 97.29% higher than that of the company.
Cara Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cara Therapeutics's current stock value. Our valuation model uses many indicators to compare Cara Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cara Therapeutics competition to find correlations between indicators driving Cara Therapeutics's intrinsic value. More Info.Cara Therapeutics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cara Therapeutics' earnings, one of the primary drivers of an investment's value.About Cara Therapeutics Financial Statements
Cara Therapeutics stakeholders use historical fundamental indicators, such as Cara Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cara Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cara Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cara Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 55 people.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.